AACR: Human Papillomavirus Tied to Lung Cancer

Article

Several high-risk forms of human papillomavirus (HPV) antibodies may be associated with an increased risk of lung cancer, according to research presented at the annual meeting of the American Association for Cancer Research, held April 2 to 6 in Orlando, Fla.

MONDAY, April 4 (HealthDay News) -- Several high-risk forms of human papillomavirus (HPV) antibodies may be associated with an increased risk of lung cancer, according to research presented at the annual meeting of the American Association for Cancer Research, held April 2 to 6 in Orlando, Fla.

Devasena Anantharaman, Ph.D., of the International Agency for Research on Cancer in Lyon, France, and colleagues determined the presence of several high-risk and low-risk types of HPV using serological tests in 1,633 individuals with lung cancer and 2,729 matched controls from six central European countries.

The investigators found that antibodies to proteins in eight types of high-risk HPV were significantly increased among individuals with lung cancer. However, a low prevalence of antibodies to all types of HPV tested was found among controls. The investigators also found that smoking did not account for this effect, as the results were consistent in current smokers, former smokers, and those who never smoked.

"While a number of previous studies have demonstrated the presence of HPV in lung cancer, their statistical power has been limited by small average sample size and variations in methodology," Anantharaman said in a statement. "We know that HPV can reach the lung, but whether HPV can cause frank malignancies is a question we hope to answer."

Abstract No. 1890More Information

Related Content

Gynecologic Oncology

Recent Videos
Fertility counseling for oncology patients | Image Credit: allhealthtv.com
New algorithm to identify benign lesions developed | Image Credit: nemours.mediaroom.com
Anne Banfield, MD | Image Credit: © Medstar
Jonathan Miller, MD
sentinel lymph node mapping
Related Content
© 2024 MJH Life Sciences

All rights reserved.